MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03236nam a22003857a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
210401s202020120 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1355-6037 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1136/heartjnl-2020-317928 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
heartjnl-2020-317928 [pii] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC7925818 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
33229362 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. |
| 251 ## - Source |
|---|
| Source |
Heart. 2020 Nov 23 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Heart. 2020 Nov 23 |
| 253 ## - Journal Name |
|---|
| Journal name |
Heart (British Cardiac Society) |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2020 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2021 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
aheadofprint |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2021-04-01 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: Rilonacept led to rapid and sustained improvement in pain, inflammation (CRP and pericarditis manifestations) and HRQOL. CSs were successfully tapered or discontinued; safety was consistent with known rilonacept safety profile. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: This multicentre, open-label study enrolled adult patients with idiopathic or postpericardiotomy RP, symptomatic (>=2 pericarditis recurrences) or corticosteroid (CS) dependent (>=2 recurrences prior). Patients received rilonacept 320 mg SC load/160 mg SC weekly maintenance in a 6-week base treatment period (TP) followed by an optional 18-week on-treatment extension period (EP) (option to wean background therapy). |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
OBJECTIVE: Recurrent pericarditis (RP) incurs significant morbidity. Rilonacept inhibits both interleukin-1 alpha (IL-1alpha) and IL-1beta; these cytokines are thought to play a major role in RP. This phase II study evaluated rilonacept efficacy and safety in RP. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: Outcomes: pericarditis pain (numeric rating scale (NRS)) and inflammation (C reactive protein (CRP)) for symptomatic patients; disease activity after CS taper for CS-dependent patients. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
SECONDARY OUTCOMES: health-related quality of life (HRQOL), pericarditis manifestations and additional medications. 25 unique patients enrolled, while 23 completed the EP (seven colchicine failures and five CS failures). In symptomatic patients, NRS and CRP decreased; response was observed after first rilonacept dose. NRS decreased from 4.5 at baseline to 0.7, and CRP decreased from 4.62 mg/dL at baseline to 0.38 mg/dL at end of TP. Median time to CRP normalisation: 9 days. Pericarditis manifestations resolved. 13 patients on CS at baseline completed the EP; 11 (84.6%) discontinued CS, and 2 tapered; CRP and NRS remained low without recurrence. Mean HRQOL scores improved in symptomatic patients. One serious adverse event (SAE) resulted in discontinuation of rilonacept. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
TRIAL REGISTRATION NUMBER: NCT03980522. Copyright ♭ Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Washington Hospital Center |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Internal Medicine |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Ertel, Andrew |
| 790 ## - Authors |
|---|
| All authors |
Abbate A, Beutler A, Cremer PC, Ertel A, Fang F, Klein AL, LeWinter M, Lin D, Luis SA, Nasir S, Paolini JF |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1136/heartjnl-2020-317928">https://dx.doi.org/10.1136/heartjnl-2020-317928</a> |
| Public note |
https://dx.doi.org/10.1136/heartjnl-2020-317928 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
